Engineering Approaches in Human Gamma Delta T Cells for Cancer Immunotherapy

被引:52
|
作者
Fisher, Jonathan [1 ]
Anderson, John [1 ]
机构
[1] UCL, London, England
来源
FRONTIERS IN IMMUNOLOGY | 2018年 / 9卷
基金
英国惠康基金;
关键词
gamma delta; chimeric antigen receptor; adoptive transfer; alpha beta T cells; cancer immunotherapy; CHIMERIC-ANTIGEN-RECEPTOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; MELANOMA-ASSOCIATED ANTIGEN; GENE-THERAPY; ANTITUMOR-ACTIVITY; NK CELLS; ADOPTIVE IMMUNOTHERAPY; NONPEPTIDE ANTIGENS; HUMAN NEUROBLASTOMA; PRESENTING CELLS;
D O I
10.3389/fimmu.2018.01409
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Sharing both innate and adaptive immune properties,gamma delta T cells are attractive candidates for cellular engineering. As the cancer immunotherapy field becomes increasingly busy, orthogonal approaches are required to drive advancement. Engineering of alternative effector cell types such as gamma delta T cells represents one such approach. gamma delta T cells can be modified using many of the techniques used in alpha beta T cell engineering, with the added advantage of innate-like tumor recognition and killing. Progress has been made in T-cell receptor transfer to and from gamma delta T cells as well as in a number of chimeric antigen receptor-based strategies. As the cancer immunotherapy field moves beyond repetitive iteration of established constructs to more creative solutions, gamma delta T cells may offer an attractive chassis to drive anti-tumor responses that are not only broader, but also possess a more favorable safety profile.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Engineering CAR-T cells: Design concepts
    Srivastava, Shivani
    Riddell, Stanley R.
    TRENDS IN IMMUNOLOGY, 2015, 36 (08) : 494 - 502
  • [42] Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells
    Xu, Xiao-Jun
    Tang, Yong-Min
    CANCER LETTERS, 2014, 343 (02) : 172 - 178
  • [43] CAR-T cells for cancer immunotherapy-the barriers ahead and the paths through
    Zhang, Qiqi
    Zu, Cheng
    Hu, Yongxian
    Huang, He
    INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2022, 41 (06) : 567 - 581
  • [44] Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives
    Coscia, Marta
    Vitale, Candida
    Cerrano, Marco
    Maffini, Enrico
    Giaccone, Luisa
    Bocca-Doro, Mario
    Bruno, Benedetto
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2019, 24 : 1284 - 1315
  • [45] Immunosurveillance by gamma delta T cells - lessons from the cancer field
    A C Hayday
    E Binda
    A Robert
    M Serrano
    F Dieli
    Journal of Translational Medicine, 8 (Suppl 1)
  • [46] Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy
    Foley, Colleen R.
    Swan, Sheridan L.
    Swartz, Melody A.
    JOURNAL OF IMMUNOLOGY, 2024, 212 (02) : 188 - 198
  • [47] Coengineering specificity, safety, and function into T cells for cancer immunotherapy
    Attianese, Greta Maria Paola Giordano
    Ash, Sarah
    Irving, Melita
    IMMUNOLOGICAL REVIEWS, 2023, 320 (01) : 166 - 198
  • [48] Natural killer cells as a promising therapeutic target for cancer immunotherapy
    Kim, Nayoung
    Lee, Hyeon Ho
    Lee, Hyo-Jung
    Choi, Woo Seon
    Lee, Jinju
    Kim, Hun Sik
    ARCHIVES OF PHARMACAL RESEARCH, 2019, 42 (07) : 591 - 606
  • [49] Reprogramming T-cells for adoptive immunotherapy of ovarian cancer
    Genta, Sofia
    Ghisoni, Eleonora
    Giannone, Gaia
    Mittica, Gloria
    Valabrega, Giorgio
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (04) : 359 - 367
  • [50] Editorial: Emerging engineering approaches in cancer immunotherapy
    Xu, Jialu
    Ming, Xin
    Min, Yuanzeng
    Wang, Chao
    FRONTIERS IN ONCOLOGY, 2022, 12